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Abstract
Objective To investigate and compare drug prescription
patterns in children admitted to a paediatric general med-
ical ward in five countries.
Methods A prospective cohort study conducted on
paediatric medical wards in the UK, Germany, Australia,
Hong Kong (HK) and Malaysia. Data were collected over 3
months in each country except in Australia (1 month). All
medications prescribed were classified according to the
WHO Anatomical Therapeutic Chemical (ATC) classifi-
cation. For each drug, frequency of prescriptions and
patient exposures were calculated for ATC anatomical and
therapeutic levels overall and by country.
Results One thousand two hundred and seventy-eight
patients were included (Australia 146, Germany 376, UK
313, HK 143 and Malaysia 300); 89.2 % of patients (1140)
received medications, median 3 (interquartile range 2–5)
drugs per patient. 5367 drugs were prescribed. The most
frequently prescribed therapeutic groups in all countries
were: systemic antibacterials (1355; 25.2 %), analgesics/
non-steroidal anti-inflammatory drugs (NSAIDs) (1173;
21.8 %) and drugs for obstructive airway diseases (472;
8.8 %). Overall, 65.1 % (742) of patients received at least
one systemic antibacterial, 63.7 % (726) received one or
more analgesic/NSAIDs, and 23.6 % (269) received ‘drugs
for obstructive airway diseases’. The number of patients
exposed to these groups differed significantly between
countries (p\ 0.05). Paracetamol was the most frequently
prescribed in all countries, but metamizole was only used
in Germany. Morphine was mainly prescribed in the UK.
Conclusion This study provides an overview of drug use
patterns in five culturally and ethnically diverse countries.
The most frequently used therapeutic groups were similar,
but the proportion of patients treated differed between
countries. Also within a therapeutic group the specific drug
used varied between countries.
Key Points
The most utilised therapeutic groups in the
participating countries were systemic antibacterials
(25.2 %) and analgesics/NSAIDs (21.8 %);
however, the use of specific drugs within a
therapeutic group differed among countries.
Prescription patterns varied among participating
countries, which might be related to differences in
treatment strategies or different clinical diagnoses of
children in various parts of the world.
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1 Introduction
Drug utilisation is an important component of many
research initiatives that examine the clinical and economic
effectiveness of pharmacotherapy [1]. The World Health
Organization (WHO) defines drug utilisation as ‘‘the
marketing, distribution, prescription and use of drugs in a
society, with special emphasis on the resulting medical,
social and economic consequences’’ [2]. Thus, the goal of
drug utilization research is to facilitate the rational use of
drugs in populations, and provide evidence of prescribing
patterns. Based on this evidence, measures may be
recommended to improve prescribing behaviour.
Most of the previous drug utilisation studies on paedi-
atric patients were conducted to describe how specific
drugs or certain groups of drugs were used, for example,
the prescribing trends with antimicrobials [3], antidiabetic
drugs [4] and psychotropic drugs [5–7], or to evaluate how
practice in children differed from the recommendations in
the summary of product characteristics, adult dosing
guidelines or hospital formularies [8, 9].
Sturkenboom et al. [10] have probably provided the most
comprehensive overview of primary-care prescription
patterns in a large multinational European paediatric popu-
lation. This study found similarities between countries, e.g.
children less than 2 years of age had the highest prescription
rate, and also differences, e.g. prescription of nervous system
drugs were higher in the UK compared to the other two
countries.Another community setting study conducted in one
million Canadian children showed that the drugs used and the
rates of use were highly dependent on age [11]. However,
there are limited international data available for comparison
of secondary care prescription patterns in children. Inmost of
the published studies to date different settings and different
methods for data collection and analysis were used, which
makes it difficult to compare the data [12–15].
Consequently, more systematic drug utilisation research
is needed, particularly internationally for hospitalised chil-
dren.We conducted a prospective, multicentre study, using a
common protocol, standardised data collection methods and
terminologies to describe and compare the drug prescription
patterns in hospitalised children in a paediatric general
medical ward in five countries, both European and non-
European, with different cultures and ethnicity.
2 Methods
The findings presented are derived from secondary use of
data collected in a previous study [16] conducted in
2008–2009; the study methodology has been reported
previously [16] and the following is a brief summary.
A prospective multicentre cohort study was conducted
in the paediatric general medical ward of a hospital in
five countries: Australia, Germany, China [Hong Kong
(HK)], Malaysia and the UK. Data were collected over a
3-month period in each country except Australia where it
was collected for 1 month only due to resource limita-
tions: Australia 10 November 2008–10 December 2008;
Germany 15 October 2008–14 January 2009; UK 14
January 2009–14 April 2009; HK 15 August 2009–14
November 2009; Malaysia 1 April 2009–30 June 2009.
Data were collected using a web-based data entry appli-
cation designed specifically for this study. All children
aged 0–18 years admitted to a paediatric general medical
ward during the study period and who stayed for C24 h
were included.
The data collected comprised patient demographics and
drug prescription details including route of administration
and reported diagnosis.
For standardisation the WHO Anatomical Therapeutic
Chemical (ATC) classification system for medication was
used by all participating hospitals [17]. WHO-ATC uses a
hierarchical system for classifying medicines into distinct
groups at five different levels according to the organ sys-
tem which they act on and their therapeutic, pharmaco-
logical and chemical properties; anatomical main group
(level 1), therapeutic subgroup (level 2), pharmacological
subgroup (level 3), chemical subgroup (level 4),and
chemical substance (level 5). The International Classifica-
tion of Diseases version 10 (ICD 10) was used for classi-
fying diagnoses [18].
2.1 Drug Prescriptions Details
All drugs prescribed for children during admission were
collected from medication charts. This included all new
medicines prescribed during admission as well as
medicines the patient was taking prior to admission.
Each prescribed drug and each chemical compound or
combination of compounds, based on ATC classification,
was considered only once per patient irrespective of
whether the dose was changed or prescriptions were
repeated during hospitalisation. Fluid and electrolyte
infusions and total parenteral nutrition (TPN) were not
documented. For the comparison between countries, we
grouped the drug prescriptions based on various levels of
the ATC classification system [17]. Routes of adminis-
tration (e.g. oral, parenteral, topical or rectal) were
recorded.
Drug prescriptions were stratified into three groups
based on the number of prescribed drugs received per
patient during their hospitalisation: 1–4, 5–10 and
[10 drugs.
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2.2 Drug Exposure
The percentage of patients exposed to a particular thera-
peutic group in the study cohort and in each country was
calculated as the number of patients prescribed at least one
drug in a particular therapeutic group with the total number
of patients prescribed any drug in the study cohort and/or in
each country cohort as the denominator. Also, patient
exposure percentages were calculated for the following
therapeutic groups: systemic antibacterials (J01), anal-
gesics (N02), drugs for obstructive airway diseases (R03),
anti-inflammatory and antirheumatic drugs (M01),
systemic corticosteroids (H02), ‘blood substitutes and
perfusions (B05)’, ‘drugs for acid-related disorders (A02)’,
psycholeptics (N05), antiepileptics (N03) and laxatives
(A06), because these were the most frequently prescribed
therapeutic drug groups in this study. Because the usual use
of an anti-inflammatory drug is as an analgesic, N02
(analgesic) and M01 (anti-inflammatory) were combined
into one group (analgesics/NSAIDs) and patient exposure
to this combined group was calculated.
2.3 Statistical Analysis
Statistical analyses were performed using Stata 11
(StataCorp, College Station, TX, USA). For descriptive
analysis and differences between groups and countries,
Chi-squared, Kruskal–Wallis rank and Wilcoxon rank-sum
tests were used as appropriate. Significant differences were
considered at p values\0.05.
The number of drugs prescribed per patient and drug
exposures for the most frequently prescribed therapeutic
drug groups were calculated in the overall study cohort and
in each country.
Paediatric patients were grouped into three age groups
(B2, [2 to B11, [11 to B18 years), according to the
International Conference of Harmonization (ICH) classifi-
cation, in the overall study cohort and in each country [19].
3 Results
3.1 Study Population Descriptive
A total of 1278 paediatric patients were identified from five
countries. 705 (55.2 %) of the 1278 children were male
(Table 1). There was a significant difference in length of
hospital stay between countries (p\ 0.001), except
between Germany and the UK and between HK and
Malaysia, where no significant difference was found.
Overall, 1140 (89.2 %) children were prescribed at least
one medication. The majority (54.1 %; n = 617/1140)
were aged B2 years, 32.7 % (n = 373/1140) were aged[2
to B11 years, and 13.2 % (n = 150/1140) were aged[11
to B18 years (Table 1).
The most commonly reported diseases overall and in
each country were those of the respiratory system
(417/1140; 36.6 %) (Table 1).
3.2 Prescription Prevalence
Overall, 1140 (89.2 %) patients were prescribed a total of
5367 drugs. The median number of drugs prescribed per
patient was three [interquartile range (IQR) 2–5 drugs].
The majority of patients (n = 766/1140; 67.2 %) received
1–4 drugs, most of whom were aged B2 years (n = 445/766;
58.1 %); while 287 (25.2 %) patients received 5–10 drugs,
and 87 (7.6 %) were prescribed more than ten drugs
(Table 1). The average number of medicines prescribed per
patient was greatest for older children (aged between 11 and
18 years) in all countries except HK where children aged
between 2 and 11 years were prescribed the greatest number
of medicines per patient (Fig. 1).
3.2.1 Drug Use by Anatomical Class (Level 1)
Overall, systemic anti-infectives (J) were themost frequently
prescribed group (n = 1453; 27.1 %), followed by the ner-
vous system group (N) (n = 1272; 23.7 %). This pattern was
also shown in each country. However, whereas respiratory
system (R) drugs were the third most commonly prescribed
group in HK and Malaysia, in the other three countries the
alimentary tract and metabolism drugs group (A) was the
third most frequently prescribed group (Table 2).
3.2.2 Drug Use by Therapeutic Class (Level 2)
In the total cohort four therapeutic groups accounted for
55.9 % (n = 2999) of all prescriptions; the highest number
was systemic antibacterials (n = 1355; 25.2 %), followed
by analgesic drugs (n = 903; 16.8 %), drugs for obstruc-
tive airway diseases (n = 472; 8.8 %) and anti-inflamma-
tory and antirheumatic products (n = 269; 5.0 %). Similar
patterns were seen in each country for the systemic
antibacterials and analgesics. Drugs for obstructive airway
diseases were significantly more commonly prescribed in
Malaysia compared to the other countries (p\ 0.001).
3.2.3 Drug Use by Chemical Substance (Level 5)
Overall, paracetamol was the most frequently prescribed
drug (n = 640; 11.9 %), followed by ibuprofen (n = 248;
4.6 %) and salbutamol (n = 226; 4.2 %) (Table 3). A
similar pattern was seen in each country for paracetamol
prescriptions, except in Germany where ibuprofen
(n = 120; 8.9 %) was the most frequently used drug. The
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second most frequently prescribed drug varied between
countries: in the UK it was ibuprofen (n = 108; 5.4 %), in
Malaysia cefuroxime (n = 152; 16.8 %), in HK salbutamol
(n = 17; 4.8 %), in Australia gentamicin (n = 36; 4.8 %)
and in Germany it was metamizole (n = 115; 8.6 %),
which was only prescribed in Germany.
Morphine was only prescribed in the UK (53/2010;
2.6 %) and Australia (12/753; 1.6 %); 92.8 % (n = 39/42)
of total fluticasone prescribing occurred in Malaysia, where
4.3 % (n = 39/904) of prescriptions were for this
medication.
3.2.4 Routes of Administration
Overall the oral route had the highest percentage of
prescriptions (n = 2816/5367; 52.5 %), followed by the
parenteral route (n = 1744/5367; 32.5 %) and inhalation
(n = 468/5367; 8.7 %). The pattern was similar in each
country cohort (Table 4). Topical (n = 149/5367; 2.8 %)
and rectal (n = 135/5367; 2.5 %) routes were used less
frequently.
Oral and parenteral routes were the most frequently used
routes of administration for the five most frequently
prescribed therapeutic groups. The majority of systemic
antibacterials (n = 979/1355; 72.2 %) were given
parenterally, while the majority of analgesics/NSAIDs
(n = 922/1172; 78.7 %) were given orally.
Salbutamol was given via both inhalation and parental
routes only in the UK (n = 58 and n = 7 prescriptions,
respectively).
Of the total rectal prescriptions, 73.3 % (n = 99/135)
occurred in Germany, where 7.4 % (n = 99/1343) of pre-
scriptions were for rectal drugs. Of these, 56.6 % (n = 56/99)
were paracetamol suppositories and 17.2 % (n = 17/99) were
for sorbitol (laxative) administration.
With regard to topical prescriptions, 67.8 % (n = 101/149)
occurred in the UK, where 5 % (n = 101/2010) of pre-
scriptions were for a topical medication. Of these, 16.8 %
(n = 17/101) were for lidocaine (in combination) as an
anaesthetic.
3.3 Drug Exposure
The exposure of patients to the most frequently prescribed
therapeutic groups in each country and overall, stratified by
age groups, is shown in Table 5.
There was a significant difference between countries
regarding the number of patients exposed to each of the
most commonly prescribed therapeutic groups (p\ 0.05).
Use of ‘blood substitutes and perfusion solutions’ was not
reported in Malaysia; a significant difference in the number
of patients exposed to this group was found between the
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3.3.1 Systemic Antibacterials
Overall, 65.1 % (n = 742) of the patients received at least
one systemic antibacterial (median 1, IQR 1–2, range
1–10). Of the 742 patients, 51.3 % (n = 381) were exposed
to one systemic antibacterial, 29.6 % (n = 220) to two
different types of antibacterials, and 19 % (n = 141) were
prescribed three or more different antibacterials. A similar
pattern was shown in most individual countries with the
exception of Australia, where the highest percentage was
for patients who received three or more different antibac-
terials (37.6 %; n = 32/85). In Malaysia the number of
patients (n = 244/288; 84.7 %) exposed to systemic
antibacterials was higher than in the other countries
(p\ 0.001). Overall, 99.5 % (n = 1348/1355) of the pre-
scriptions for this group were given parenterally (n = 979/
1348; 72.6 %) or orally (n = 369/1348; 27.4 %). This
pattern of a high percentage of the prescriptions for sys-
temic antibacterials (J01) given parenterally was also
shown in the individual countries [Australia 145/189
(76.7 %), Germany 213/291 (73.2 %), UK 252/397
(63.5 %), HK 41/61 (67.2 %) and Malaysia 328/417
(78.7 %)].
3.3.2 Analgesics and Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs)
At least one analgesic was received by 60.9 % (n = 694) of
patients (median 1, IQR 1, range 1–5) and 22.1 % (n = 252)
received at least one ‘anti-inflammatory and anti-rheumatic
product’ (median 1, IQR 1, range 1–2) (Table 5).
When analgesic and NSAID prescriptions were com-
bined into one group (Analgesics/NSAIDs), the exposure
rates varied between 84.2 % in the UK and 35.3 % in HK
(p\ 0.001). In the overall cohort there was no significant
difference within age groups in the number of patients
exposed to this combined group (p = 0.899), nor was there
in each country.
3.3.3 Drugs for Obstructive Airway Diseases
Overall, 23.6 % (n = 269) of patients received at least one
of the ‘drugs for obstructive airway diseases’ (medium 1,
IQR 1–2, range 1–6). Overall, there was a significant dif-
ference in the exposure rates among age groups (p\ 0.05),
but this was not the case among age groups within each
country.
Also there was a significant difference in the percentage
of patients exposed to this therapeutic group between the
countries (p\ 0.01): highest in Malaysia (n = 97/288;
33.7 %) and lowest in Germany (n = 37/293; 12.6 %)
(Table 5).
4 Discussion
The study showed that on average 89.2 % of the hospi-
talised paediatric patients in the study cohort were pre-
scribed one or more drugs (new and/or continued from the
community) during their admission, although the number
of children exposed to drug therapy varied significantly
between the countries. In Germany 77.9 % of patients
received pharmacological treatment whereas in the UK and
Malaysia it was higher (96.8 and 96.0 %, respectively).
This may be due in part to the fact that in Germany par-
ticularly young children with ‘commotio cerebri’ are
commonly hospitalised for monitoring purposes which may
not be the case in the other countries.
Fig. 1 Average number of
drugs prescribed per patient
stratified by age group and
country
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Of significance is that the majority of poly-pharmacy
occurs in older children. Whilst there may be many reasons
for this, we could hypothesis that this is either due to
co-morbidities increasing through childhood, increased
severity of disease requiring multiple medications or poor
management in terms of medicines being added but not
being stopped. In line with these thoughts, the lowest tier
(prescribed 1–4 drugs) was represented by a majority of
children B2 years old. This might be because most young
children have a single clinical condition at this stage of life
and thus have a low medication need. However, it might
also suggest that prescribing is carried out more conser-
vatively in this age group, due to a lack of experience, lack
of evidence base or lack of formulary drugs that the clin-
ician is able to prescribe.
The average number of different drugs prescribed per
patient was very high in some countries ([10 drugs per
patient in the UK). This in itself is an interesting fact, with
Table 2 Number of drugs prescribed per country stratified by anatomical levels of the Anatomical Therapeutic Chemical (ATC) classification












Anti-infectives for systemic use (J) 199 (26.4) 318 (23.7) 435 (21.6) 73 (20.4) 428 (47.3) 1453 (27.1)
Antibacterials for systemic use (J01) 189 (25.1) 291 (21.7) 397 (19.8) 61 (17.1) 417 (46.1) 1355 (25.2)
Antivirals for systemic use (J05) 7 (0.9) 21 (1.6) 19 (0.9) 4 (1.1) 3 (0.3) 54 (1.0)
Nervous system (N) 163 (21.6) 311 (23.2) 516 (25.7) 100 (28.0) 182 (20.1) 1272 (23.7)
Analgesics (N02) 123 (16.3) 225 (16.8) 346 (17.2) 51 (14.3) 158 (17.5) 903 (16.8)
Antiepileptics (N03) 9 (1.2) 53 (4.0) 45 (2.2) 23 (6.4) 23 (2.5) 153 (2.9)
Psycholeptics (N05) 21 (2.8) 23 (1.7) 64 (3.2) 17 (4.8) 1 (0.1) 126 (2.3)
Anaesthetics (N01) 5 (0.7) 2 (0.1) 54 (2.7) 2 (0.6) – 63 (1.2)
Respiratory system (R) 59 (7.8) 107 (8.0) 255 (12.7) 62 (17.4) 175 (19.4) 658 (12.3)
Drugs for obstructive airway diseases (R03) 45 (6.0) 60 (4.5) 174 (8.7) 28 (7.8) 165 (18.3) 472 (8.8)
Antihistamines for systemic use (R06) 6 (0.8) 12 (0.9) 38 (1.9) 11 (3.1) 6 (0.7) 73 (1.4)
Cough and cold preparations (R05) 7 (0.9) 22 (1.6) 32 (1.6) 3 (0.8) 2 (0.2) 66 (1.2)
Musculoskeletal system (M) 26 (3.5) 129 (9.6) 169 (8.4) 7 (2.0) 3 (0.3) 334 (6.2)
Anti-inflammatory and antirheumatic products
(M01)
16 (2.1) 119 (8.9) 130 (6.5) 2 (0.6) 2 (0.2) 269 (5.0)
Muscle relaxants (M03) 3 (0.4) 5 (0.4) 37 (1.8) 2 (0.6) 1 (0.1) 48 (0.9)
Systemic hormonal preparations, excluding sex
hormones and insulin (H)
54 (7.2) 67 (5.0) 76 (3.8) 5 (1.4) 58 (6.4) 260 (4.8)
Corticosteroids for systemic use (H02) 52 (6.9) 54 (4.0) 73 (3.6) 1(0.3) 58 (6.4) 238 (4.4)
Blood and blood-forming organs 43 (5.7) 57 (4.2) 142 (7.1) 29 (8.1) 9 (1.0) 280 (5.2)
Blood substitutes and perfusion solutions (B05) 8 (1.1) 23 (1.7) 87 (4.3) 21 (5.9) – 139 (2.6)
Antianaemic preparations (B03) 12 (1.6) 26 (1.9) 37 (1.8) 1 (0.3) 4 (0.4) 80 (1.5)
Alimentary tract and metabolism (A) 157 (20.8) 238 (17.7) 294 (14.6) 39 (10.9) 29 (3.2) 757 (14.1)
Drugs for acid-related disorders (A02) 32 (4.3) 28 (2.1) 90 (4.5) 18 (5.0) 8 (0.9) 176 (3.3)
Laxatives (A06) 16 (2.1) 34 (2.5) 67 (3.3) 7 (2.0) 1 (0.1) 125 (2.3)
Drugs for functional gastrointestinal disorders
(A03)
9 (1.2) 9 (0.7) 38 (1.9) 2 (0.6) 6 (0.7) 64 (1.2)
Antidiarrhoeals, intestinal anti-inflammatory/anti-
infective agents (A07)
13 (1.7) 17 (1.3) 25 (1.2) 1 (0.3) 6 (0.7) 62 (1.2)
Drugs used in diabetes (A10) 21 (2.8) 2 (0.1) 1 (0.05) 9 (2.5) – 33 (0.6)
Cardiovascular system 18 (2.4) 41 (3.1) 49 (2.4) 8 (2.2) 19 (2.1) 135 (2.5)
Diuretics (C03) 11 (1.5) 11 (0.8) 32 (1.6) 1 (0.3) 12 (1.3) 67 (1.2)
Antineoplastic and immunomodulating agents 7 (0.9) 39 (2.9) 5 (0.2) – – 51 (1.0)
Immunosuppressive agents (L04) 5 (0.7) 36 (2.7) 4 (0.2) – – 45 (0.8)
The numbers of prescriptions for therapeutic groups do not add up to the total number of prescriptions for anatomical level as there are other
therapeutic groups included but only in small numbers and hence not presented in the table
n Total number of prescriptions, HK Hong Kong
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a perception that children use relatively few medicines.
The variation, however, is of more interest and indicates
that countries either have different reliance on medicines as
a medical intervention or that paediatric general medical
wards are used for sicker patients (more need for medici-
nes) in some countries than others.
4.1 Drug Prescriptions
Overall and in each country individually, the majority of
the paediatric patients (67 %) received 1–4 drugs.
4.1.1 Route of Administration
In our study we found some differences in the route of drug
administration; Germany had the highest use of the rectal
route. There are cultural and sexual restrictions to consider
regarding this route as there is reluctance in some societies
to administer drugs via the rectal route [20]. This might be
related to child protection concerns, so rectal administra-
tion is only used in exceptional situations when the oral
route is difficult to use, such as in a vomiting child [20, 21].
A recent review which investigated the reasons for the
unpopularity of the rectal route for drug administration to
children concluded that more effort needs to be focused on
educating parents and care providers on the benefits of this
route for drug administration [22].
Also, we found that administration of therapy by
inhalation was particularly common in Malaysia. This is
probably linked to the high use of drugs for obstructive
airway diseases which is higher in Malaysia compared to
the other countries.
The topical route was commonly used in the UK mainly
for the administration of anaesthetics. It appears that
particular caution is paid in the UK to avoid pain and
distress when invasive procedures such as inserting a
cannula are performed.
4.2 Drug Exposure: Main Therapeutic Classes
We need to consider that differences in the climate
between participating countries may also have affected the
type of reported diseases, and consequently prescribing
pattern. Malaysia has a tropical climate and influenza
symptoms peak during the rainy season, and the data
collection period was during a considerably wet season.
HK is a temperate southern hemisphere climate, and the
data were collected between the summer–winter seasons.
The UK and Germany are northern hemisphere countries
and data were collected between the autumn–spring sea-
sons, while Australia is a southern hemisphere country and
at the time of the study it was spring–summer.
4.2.1 Antibacterials
In a German study, it was found that antibacterials were the
most common drug class used to treat children in hospital
[15]. Our study had similar findings. Antibiotics with
broad-spectrum activity were most frequently prescribed.
The increased use of broad-spectrum antibacterials,
compared to those with a narrow spectrum of activity, in
primary and secondary care has been recognised in previ-
ous studies [23, 24]. Fossum et al.’s study [24] investigated
the antibiotic prescription patterns in primary healthcare in
Norway, and found that there was an overuse of macrolides
and penicillins with an extended spectrum. However,
patients admitted to hospital are often severely ill and need
immediate antibiotic therapy. Thus empirical antibiotic
therapy to treat a broad spectrum of bacteria is usually
commenced. Once the antibiogram is available the















Oral 421 (55.9) 702 (52.3) 1094 (54.4) 197 (55.2) 402 (44.5) 2816 (52.5)
Parenteral 257 (34.1) 451 (33.6) 586 (29.2) 92 (25.8) 358 (39.6) 1744 (32.5)
Inhalation 43 (5.7) 67 (5.0) 190 (9.5) 27 (7.6) 141 (15.6) 468 (8.7)
Topical 19 (2.5) 3 (0.2) 101 (5.0) 25 (7.0) 1 (0.1) 149 (2.8)
Rectal 5 (0.7) 99 (7.4) 24 (1.2) 7 (2.0) 135 (2.5)
Nasal 1 (0.1) 16 (1.2) 14 (0.7) 9 (2.5) 2 (0.2) 42 (0.8)
Sublingual/buccal 2 (0.3) 2 (0.1) 1 (0.05) 5 (0.1)
Transdermal 4 (0.5) 4 (0.1)
Vaginal 1 (0.1) 1 (0.02)
Intravesical 1 (0.1) 1 (0.02)
Data presented as n (%)
n Number of prescriptions, HK Hong Kong
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treatment is adjusted to eliminate the specific bacteria
identified for a specific patient.
In our study, 48.7 % of patients treated with systemic
antibacterials received two or more different types of
antibacterials, which might have led to the high numbers of
antibacterial prescriptions in all countries. The fact that
different broad-spectrum antibiotics were used in each
country may be due to differences in disease patterns and/
or variation in guidelines. The high proportion of patients
prescribed systemic antibacterial drugs in Malaysia may be
because Malaysia is a tropical country and infectious
diseases including respiratory tract infections occur with a
reported prevalence of 61.3 % [16]. Our study found that
the proportion of total prescriptions for antibacterials was
much higher in Malaysia than in the other countries; also
the proportion of patients with respiratory system disease
was high, which supports this proposal.
The variation in the drugs used among the participating
countries could be determined by cultural influences,
national guidelines, local or regional policy, local resis-
tance patterns, condition for which the child was admitted,
knowledge of appropriate antibiotic prescribing and avail-
ability of drugs on the market.
4.2.2 Analgesics and NSAIDs
Paracetamol was widely used in all countries, but the use of
other analgesics varied, e.g. metamizole was only used in
Germany, whilst in the UK and Australia morphine was the
most frequently prescribed analgesic after paracetamol.
This is in line with previous studies from Germany,
Australia, the UK, USA and Italy [10, 15, 25–29]. Though
metamizole is a very effective analgesic and antipyretic
and can be used in both adults and children, it is not
available in some countries, e.g. the UK, because of its
association with rare but life-threatening agranulocytosis
and aplastic anaemia [30–32].
Our study shows there are differences between countries
in the number of patients exposed to analgesics/NSAIDs,
being highest in the UK and lowest in HK. Use of both an
analgesic and an anti-inflammatory drug alternatively, e.g.
paracetamol and ibuprofen, was seen commonly in some
countries such as Germany, but was less frequent in other
countries. It was not possible to ascertain the reason(s) for
the differences in the prescription patterns of these drugs
among the participating countries as we did not investigate
the formularies of the participating hospitals nor their
guidelines (if any), but a possible explanation could be due
to differences in therapeutic practices, availability of drugs
or beliefs in each country. Differences in clinical practice
and prescribing behaviour between countries and even
among healthcare settings within countries have been
shown in previous studies [12, 26, 33, 34].
The study provides an interesting finding regarding
differences in pain therapy among the participating coun-
tries: in the UK up to 90 % of patients received analgesic
therapy whereas only 50 % did in some other countries and
none of the adolescents in Malaysia received this treat-
ment. However, it has been shown there is often insuffi-
cient pain treatment in paediatric patients [35] and our data
indicate this may still be the case at some hospitals.
4.2.3 Drugs for Obstructive Airway Diseases
Our study results show a significant difference between
countries in the percentage of patients exposed to this drug
group, being highest in Malaysia and lowest in Germany.
This could be explained by the high percentage of patients
with respiratory system diseases and the tropical climate of
Malaysia [36]. The use of two routes of administration for
some drugs was found in some countries, for example the
use of salbutamol via both inhalation and parenteral routes
in the UK, but only by inhalation in the other four coun-
tries. The use of one drug via two different routes of
administration has been shown to increase the risk of
adverse drug reactions [16]. One of the reasons for such
differences in practice might be related to the severity of
the disease being treated or to variations in hospital
guidelines.
4.3 Strengths and Limitations
This multicentre study provides useful information on drug
utilisation in hospitalised paediatric patients admitted to
paediatric general medical wards, from five hospitals in
five countries. Data were collected prospectively, using the
same protocol. Standardised data collection methods and
terminologies enabled comparisons to be made between the
countries.
However, this study has several limitations. It was
conducted on paediatric general medical wards, so there
may be differences between countries in the type of clinical
conditions in patients admitted to these wards. If a hospital
has specialist wards, e.g. a neurology or a metabolic ward,
as in the UK, then that hospital would not admit these
patients to a paediatric general medical ward, whilst those
without specialist wards would. Another limitation is the
seriousness and/or severity of the diagnosis reported on
admission was not recorded, therefore some countries may
have admitted more serious cases, which could help to
explain the differences in drug use patterns.
The sample size from two hospitals, Australia and Hong
Kong, was small. This was due to resource limitations in
Australia which resulted in only 1 month of data collection.
The spread of pandemic flu (influenza A H1N1) during the
second half of 2009 in Hong Kong led to restrictions in
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ward visits for research, thus a smaller number of patients
were recruited.
Also, although we limited the period to complete data
collection from all countries to be within 1 year, we did
not limit to it one season. Thus seasonal variation
between countries might have an impact on the nature
and/or number of admissions and thus on the prescription
patterns.
Lack of data on the impact of cultural practices and lack
of knowledge on formularies/guidelines are other
limitations.
The findings in this paper were derived from the
secondary use of data collected in a study of adverse drug
reactions [16] in 2008–2009. However, the findings
provide useful data on drug use in paediatric general
medical wards in the countries that participated.
4.4 Implications for Practice and Research
This study may also help to prioritise drug utilisation
research in children as it raises the need for more research
on the use of different routes for drug administration, the
use of opioids and combined analgesics. Also, the high use
of antibacterials and differences in the use of specific
antibiotics raises concerns for antibacterial resistance;
further investigation is needed to determine the reasons for
this, i.e. disease patterns, severity of disease or treatment
strategies. Such information may help to improve the safety
of drugs used in paediatric patients.
5 Conclusion
This multicentre study provides useful information on drug
utilisation in children admitted to the paediatric general
medical ward of five hospitals in five countries, culturally
and ethnically diverse. It shows that the most frequently
used therapeutic drugs were similar, but the proportion of
patients treated differed between the countries. Within a
therapeutic group the specific drug used varied from
country to country. The prescription patterns differed
among the countries, which might be related to differences
in clinical practice regarding treatment strategies of pae-
diatric drug therapy in these countries or differences in
diagnoses on admission.
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